CAR-T cell therapy for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have tried at least 3 different types of myeloma treatments and they didn't work or your myeloma came back within 6 months.
- Your myeloma cells have a protein called GPRC5D (more than 10% of cells).
- You have measurable signs of myeloma in your blood or urine.
- You are in fairly good health (able to do light activities) and your organs are working well enough.
- You do not have active infections, other cancers, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.